A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
KEY INCLUSION CRITERIA:
KEY EXCLUSION CRITERIA:
Ciudad Autonoma de Bs. As., CBA 1431, Argentina
Ciudad Autonoma de Bs. As., CBA C1120AAT, Argentina
Ciudad Autonoma de Bs. As., CBA C1181ACH, Argentina
Hyderabad, Andhra Pradesh 500 082, India
Hyderabad, Andhra Pradesh 500001, India
Hyderabad, Andhra Pradesh 500004, India
Hyderabad, Andhra Pradesh 500012, India
Hyderabad, Andhra Pradesh 500063, India
Hyderabad, Andhra Pradesh 500082, India
Secunderabad, Andhra Pradesh 500003, India